{"id":14455,"date":"2012-01-16T09:30:00","date_gmt":"2012-01-16T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/i-ceo-temono-mancanza-capitale-e-innovazione\/"},"modified":"2012-01-16T09:30:00","modified_gmt":"2012-01-16T08:30:00","slug":"i-ceo-temono-mancanza-capitale-e-innovazione","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/i-ceo-temono-mancanza-capitale-e-innovazione\/","title":{"rendered":"CEOs fear lack of capital and innovation"},"content":{"rendered":"

Difficult access to capital, an uncertain regulatory environment, and lack of innovation and productivity in R&D are the biggest threats to growth in the US biomedical industry over the next five years, according to industry leaders asked for a survey of California Healthcare Institute, BayBio and PwC Us. <\/p>\n

<\/font><\/font><\/span><\/p>\n

The 74% of US biomedical industry CEOs, for example, said they had to delay a research or development project over the past year. And lack of funds is the main reason cited. CEO's 44% also assures that it will seek licensing deals and partnerships as a source of funding over the next 12 months, twice as many as those who said the same thing last year. <\/p>\n

<\/font><\/font><\/span><\/p>\n

Corporate venture financing is also set to become a preferred source of capital for the industry, with 30% of surveyed CEOs turning to this source over the next 12 months versus 10% last year.<\/p>\n

<\/font><\/font><\/span><\/p>\n

The research also finds that, for the CEOs of biomedical companies, the FDA is also a problem: the 80% of respondents "agree or strongly agree" that the current drug approval process has slowed the growth of the their company.<\/p>\n

<\/font><\/font><\/span><\/p>\n

Barbara Di Chiara \u2013 January 16, 2012 \u2013 PharmaKronos<\/font><\/span><\/em><\/p>\n

<\/span><\/p>","protected":false},"excerpt":{"rendered":"

Difficoltà nell’accesso ai capitali, un quadro regolatorio incerto e la mancanza di innovazione e produttività in ricerca e sviluppo sono le più grandi minacce alla crescita dell’industria biomedicale americana per i prossimi cinque anni, secondo i leader del settore interpellati per un’indagine di California Healthcare Institute, BayBio e PwC Us. Il 74% degli amministratori delegati …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14455","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14455"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}